Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at email@example.com
Mirtazapine and Carbamazepine Fail to Demonstrate Clinical and Cost Effectiveness as Alzheimer Agitation Treatments
Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.
Brexpiprazole Continues to Demonstrate Efficacy as Alzheimer Agitation Therapy Across Multiple Phase 3 Trials
Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.
Amyloid Copathology Not a Factor in Pharmacodynamic Effect of Irsenontrine in Dementia With Lewy Bodies, Parkinson Disease Dementia
Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.
Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab
Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).
Duchenne Gene Therapy SRP-9001 Wins Priority Review
The PDUFA date for SRP-9001, developed in partnership between Sarepta and Roche, is set for May 29, 2023. The BLA was submitted for accelerated approval.
Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses
In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.
CGRP Antagonist Atogepant Improves Patient-Reported Outcomes as Migraine Preventive
In a post-hoc analysis of the ADVANCE trial, atogepant 30 and 60 mg produced significant improvements in outcomes on Migraine-Specific Quality of Life Questionnaire and Activity Impairment in Migraine-Diary domains.
AXS-05 Meets Primary End Point in Phase 3 Trial of Alzheimer Agitation
Treatment with the investigational agent resulted in improvements in Alzheimer disease agitation, as well as significant delays in time to relapse and prevention of relapse.
Although Increased, Risk of Epilepsy and Seizures Following COVID-19 Remain Low
The relative risk of epilepsy or seizures after COVID-19 infection, compared with influenza infection, was more marked amongst children and non-hospitalized individuals over the 6-month time horizon.
Digital Cognitive Behavioral Therapy Significantly Improves Insomnia Symptoms
Nearly 40% of patients treated with CBT-I met the Athens Insomnia Score criteria for remission after 8 weeks of treatment compared with slightly above 10% of those on sham.
Furthering MS Treatment Selection: A Comparative Study of Peginterferon Beta-1a vs Interferon Beta-1a
Peginterferon beta-1a, a pegylated form of interferon designed to maintain biologic effects in the body for longer periods, is being evaluated against CinnaGen’s interferon beta-1a formulation, CinnoVex.
Cell Therapy NRTX-1001 Shows Significant Effect on Drug-Resistant Epilepsy in Early Data
NRTX-1001, an injectable suspension of high-purity inhibitory neurons, is currently being assessed in a phase 1/2 trial that includes a dose-escalation period comprising of 10 individuals with mesial temporal lobe epilepsy.
Aquatic Therapy May Positively Impact Fatigue, Balance in Multiple Sclerosis
Compared with conventional treatments, which included routine pharmaceutical treatments or occupational therapy without exercise, aquatic therapy showed several benefits in physical, cognitive, and psychosocial fatigue for patients with MS.
IMU-838 Treatment Associated With Low Rate of Confirmed Disability Worsening in Relapsing MS
Nearly 95% of patients treated with vidofludimus calcium were free from 12-week confirmed disability worsening events at week 96 of the open-label extension trial.
Continuous Subcutaneous Carbidopa/Levodopa Demonstrates Benefits in Parkinson Disease Motor Fluctuations, OFF Time
Over a 12-week treatment period, treatment with continuous subcutaneous carbidopa/levodopa resulted in significantly greater increase in ON time and reduced OFF time, while demonstrating a safe profile.
Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
ACU193, an antibody developed based on its selectivity for soluble amyloid-ß oligomers, is currently being assessed in a phase 1 trial, with a potential phase 2/3 trial in the near future.
International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype
Through a culmination of previous research, the International Advisory Committee on Clinical Trials in Multiple Sclerosis suggests that multiple sclerosis disability progression is not caused by a single uniform disease mechanism but a combination of several mechanisms that play out variably over time.
Rituximab Significantly Lessens Myasthenia Gravis Manifestations, Rescue Treatments Needed
Compared with placebo, a greater proportion of patients on rituximab met the primary end point of minimal disease manifestations at 16 weeks, and demonstrated favorable results on several secondary end points.
Epilepsy Surgical Technique Volumes, Outcomes Differ Based on Region, Other Characteristics, Report Says
US census geographic regions drove differences in both potentially curative and palliative surgery types after correcting for other characteristics.
Congestive Heart Failure and Left Atrial Enlargement Among Predictive Factors for Poststroke Atrial Fibrillation
At 12 months, patients with congestive heart failure and/or left atrial enlargement had an atrial fibrillation detection rate of 23.4% vs 5.0% for patients with neither attribute.
Headache Identified as Common Symptom in COVID-19 Variants, Mainly Delta
Six months after hospital discharge, COVD-19 headache was more frequently observed in those infected with the Delta variant vs Wuhan or Alpha variants.
NeuroVoices: Timothy Miller, MD, PhD, on the Impact of Tofersen, Antisense Therapeutics in ALS
The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.
Gore Explores Migraine Treatment Using Patent Foramen Ovale Closure in New Study
The newly announced prospective, randomized, placebo- and sham-controlled study, will include 150 patients, ages 18 to 55 years, with documented patent foramen ovale and a history of more than 1 migraine headache day per week.
Phase 2/3 Results of Zavegepant Showcase Effectiveness as Acute Migraine Medication
Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.
FDA Accepts NDA for Myasthenia Gravis Treatment Zilucoplan
Zilucoplan, a complement C5 inhibitor, demonstrated a safe and tolerable profile, while meeting its primary and secondary end points in the phase 3 RAISE trial—the basis for its new drug application.
Gantenerumab Fails to Meet End Points in Initial GRADUATE Study Data
The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.
uniQure Receives DSMB Recommendation to Resume Higher Dosing of AMT-130 in Huntington Trial
The 26-patient trial includes 10 individuals with early-manifest Huntington disease on low-dose AMT-130 and 16 in the high-dose cohort, which will continue enrollment after a DSMB found no further safety concerns.
FDA Accepts NDA for Parkinson Disease Treatment IPX203
IPX203, an oral formulation of carbidopa/levodopa, the standard treatment for Parkinson disease, demonstrated statistically significant results in improving ON time relative to immediate release CD/LD.
Addressing Stigma Improves Care in Chronic Pediatric Neurological Conditions
The Child Neurology Foundation is using community outreach and a new social services network to help children with neurological conditions feel included in contemporary society.
PRO-MSACTIVE Data Highlights Efficacy, Safety, and Patient-Reported Outcomes of Ocrelizumab in Relapsing MS
More than half of the cohort achieved no evidence of disease activity and few patients showed disability progression after 48 weeks of treatment with ocrelizumab.
2 Clarke Drive Cranbury, NJ 08512